Literature DB >> 15106951

The blood-retinal barriers system. Basic concepts and clinical evaluation.

José G Cunha-Vaz1.   

Abstract

Morphological studies demonstrating the presence in the retinal vessels of 'zonulae occludente' between the endothelial cells and physiological studies examining diffusion gradients in the vitreous after systemic or intravitreal administration of fluorescein, performed under the guidance of David Maurice, established the basis of the Blood-Retinal Barrier (BRB) concept. The BRB system is briefly reviewed as well as its role in health and disease. Regulation of the microenvironment of the retina is fundamental for appropriate retinal function and vision. The diffusional characteristics and transport functions of the BRB system may be evaluated and followed by vitreous fluorometry. Its clinical use has shown the importance of BRB alterations in a variety of retinal diseases but has been restricted by the lack of disease specificity. A recent development, the Retinal Leakage Analyzer, maps BRB alterations and has opened new perspectives for multimodal macula mapping and improved evaluation of newly available drugs that show promise for stabilizing the BRB.

Entities:  

Mesh:

Year:  2004        PMID: 15106951     DOI: 10.1016/s0014-4835(03)00213-6

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  47 in total

Review 1.  The ins and outs of cholesterol in the vertebrate retina.

Authors:  Steven J Fliesler; Lionel Bretillon
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

Review 2.  Inner blood-retinal barrier transporters: role of retinal drug delivery.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

3.  Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics.

Authors:  Ketan Hippalgaonkar; Ramesh Srirangam; Bharathi Avula; Ikhlas A Khan; Soumyajit Majumdar
Journal:  Drug Metab Dispos       Date:  2010-07-01       Impact factor: 3.922

4.  Severe bacterial endophthalmitis: towards improving clinical outcomes.

Authors:  Billy D Novosad; Michelle C Callegan
Journal:  Expert Rev Ophthalmol       Date:  2010-10

Review 5.  The blood-testis barrier and its implications for male contraception.

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Pharmacol Rev       Date:  2011-10-28       Impact factor: 25.468

6.  Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs.

Authors:  Justine R Smith; Larry L David; Binoy Appukuttan; Phillip A Wilmarth
Journal:  Am J Ophthalmol       Date:  2018-03-17       Impact factor: 5.258

Review 7.  The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited.

Authors:  Don H Anderson; Monte J Radeke; Natasha B Gallo; Ethan A Chapin; Patrick T Johnson; Christy R Curletti; Lisa S Hancox; Jane Hu; Jessica N Ebright; Goldis Malek; Michael A Hauser; Catherine Bowes Rickman; Dean Bok; Gregory S Hageman; Lincoln V Johnson
Journal:  Prog Retin Eye Res       Date:  2009-12-02       Impact factor: 21.198

8.  Efflux protein expression in human retinal pigment epithelium cell lines.

Authors:  Eliisa Mannermaa; Kati-Sisko Vellonen; Tuomas Ryhänen; Katriina Kokkonen; Veli-Pekka Ranta; Kai Kaarniranta; Arto Urtti
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

9.  Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.

Authors:  Soumyajit Majumdar; Ketan Hippalgaonkar; Ramesh Srirangam
Journal:  Drug Metab Dispos       Date:  2009-04-30       Impact factor: 3.922

10.  Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery.

Authors:  Rajendra S Kadam; Preveen Ramamoorthy; Daniel J LaFlamme; Timothy A McKinsey; Uday B Kompella
Journal:  Mol Pharm       Date:  2013-05-22       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.